Clinical trials: Steatosis
Fatty Liver Disease, Fatty Liver
Impact of Time-restricted Feeding in NAFLD
This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE).
- Conditions
- Fatty Liver Disease, Fatty Liver, Fatty Liver, Nonalcoholic
- Trial name
- NAFLD-TRF (NCT05220956)
- Testing
- Intermittent fasting, DGE diet
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
Fatty Liver Disease
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity.
- Trial name
- MASLD (NCT06720766)
- Testing
- FibbroScan and biopsy
- Where
- China
- Volunteers
- 565 people
- Sponsor
- The Third People's Hospital of Chengdu
Liver Cirrhosis, Fatty Liver
Multiparametric MR for Rapid Imaging Assessment of the Liver
The RIAL study aims to investigate whether non-invasive measurement of liver fat, iron content and fibrosis are as accurate as liver biopsy specimens in determining if patients have non-alcoholic fatty liver disease (NAFLD) or…
- Trial name
- RIAL (NCT01543646)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Oxford
Nonalcoholic Steatohepatitis (NASH)
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension.
- Trial name
- NCT04880031
- Testing
- Efimosfermin
- Where
- 48 sites in United States
- Volunteers
- 231 people
- Sponsor
- GlaxoSmithKline
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Non-Alcoholic Fatty Liver Disease, Obesity
Influence of the Diversity and Composition of the Microbiota in the Development of Pediatric Fatty Liver
The objectives of the present study are: 1) to identify the intestinal and salivary microbiota associated with the presence and severity of hepatic steatosis in children (Study I: case-control study), and 2) to develop a…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- MicroKid (NCT04575506)
- Testing
- Multidisciplinary intervention program
- Where
- 2 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01654549
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
To Assess Feasibility of the New Application
Diagnosis of Fatty Pancreas by FibroScan
Example 2: Interventional study The goal of this observational study is to learn know about the use of FibroScan in diagnosis of fatty pancreas in obese and non obese patients which done for the first time at worldwide as well as…
- Trial name
- FattyPancreas (NCT07255989)
- Testing
- meeting about the nutrition
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Benha University
Obesity, Weight Loss
Weight Loss in Adults With Obesity Using a Combination of Low Energy Diet, Group Treatment and Intragastric Balloon
In Sweden, approximately 1.3 million adults have obesity. Obesity decreases quality of life (QoL) and increases the risk of diseases such as type 2-diabetes, non-alcoholic fatty liver disease (NAFLD), cancer and cardiovascular…
- Conditions
- Obesity, Weight Loss, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04230655
- Testing
- Low energy diet using meal replacements, CBT-based group treatment, Intragastric balloon
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Region Örebro County
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
Non-Alcoholic Fatty Liver Disease
Investigation of Synbiotic Treatment in NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver condition in which fat builds up in the liver not caused by alcohol. The liver is an organ that is not designed to build up fat.
- Trial name
- INSYTE (NCT01680640)
- Testing
- Synbiotic, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Fatty Liver
The Effect of a Probiotic on Hepatic Steatosis
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States.
- Trial name
- NCT00099723
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VSL Pharmaceuticals
Growth Hormone, Recombinant, Fatty Liver
The Effect of Growth Hormone Replacement on Liver Fat
We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver.
- Trial name
- NCT00774579
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London
Nonalcoholic Fatty Liver Disease
Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
Abstract Background: Insulin resistance has an important role in the development of nonalcoholic fatty liver disease (NAFLD) and is involved in both pathological processes: hepatic steatosis and atherosclerosis.
- Trial name
- NCT01084486
- Testing
- Metformin
- Where
- Israel
- Sponsor
- Wolfson Medical Center
Non Alcoholic Fatty Liver, Obesity
Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
Effect of oral selected Probiotics (PRO) and/or Berberine (BBR) supplementation on hepatic steatosis markers, cardiometabolic profile, and gut microbiota profile in the non-alcoholic fatty liver (NAFL) - a randomized double-blind…
- Trial name
- NCT05523024
- Testing
- Probiotic, Berberine, Probiotc and Berberine
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Poznan University of Medical Sciences
MAFLD
Dihydroartemisinin for MAFLD
Brief Summary Purpose: This is a proof-of-concept clinical trial to evaluate whether Dihydroartemisinin (DHA), a medication commonly used to treat malaria, can effectively reduce liver fat in adults with Metabolic Associated…
- Trial name
- NCT07679542
- Testing
- Dihydroartemisinin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic…
- Trial name
- RESOLVE-IT (NCT02704403)
- Testing
- Elafibranor
- Where
- 326 sites in United States, Argentina and 23 more
- Volunteers
- 2,157 people
- Sponsor
- Genfit
Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.
- Trial name
- NCT06218342
- Testing
- Henagliflozin, Background medication
- Volunteers
- 156 people
- Sponsor
- Sir Run Run Shaw Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.